Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
Phase I Study of Humanized 3S193 (Anti-Lewis-Y) Antibody in Patients With Advanced Colorectal Carcinoma
Sponsor: Ludwig Institute for Cancer Research
Terminated
poor recruitment
Other terminated trials from Ludwig Institute for Cancer Research
- Cutaneous T-cell Lymphoma · Phase PHASE1 · Nov 2018
- Malignant Melanoma · Phase PHASE1/PHASE2 · Mar 2009
- Malignant Melanoma · Phase PHASE1/PHASE2 · Apr 2008
- Synovial Sarcoma · Phase PHASE2 · Jul 2007
- Neoplasms · Phase PHASE1 · May 2007
See all terminations from Ludwig Institute for Cancer Research
Other Colorectal Cancer trials with similar outcome
A PHASE1 clinical study on Colorectal Cancer, this trial is terminated or withdrawn. The trial is conducted by Ludwig Institute for Cancer Research and has accumulated 9 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Terminated PHASE1
-
Nov 2022 — Nov 2023 [monthly]
Terminated PHASE1
-
Sep 2021 — Nov 2022 [monthly]
Terminated PHASE1
Status: Completed → Terminated
▶ Show 4 earlier versions
-
Mar 2021 — Sep 2021 [monthly]
Completed PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Jul 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ludwig Institute for Cancer Research
For direct contact, visit the study record on ClinicalTrials.gov .